Session 2: Treatment of IBD
Chair: Javier Martin de Capri
08.30 – 09.00 Is there still a role for IM: should patient sex and EBV status affect our decision - M. Aloi
09.00 – 09.30 Which biologic to start and when is enough enough? - L. de Ridder
With case presentation
09.30 – 10.00 Management of refractory proctitis & pouchitis - D. Wilson
10.00 – 10.30 Joint working with surgeons - C. Spray / K. Bradshaw
10.30 – 11.00 Coffee Break
Session 3: Extraintestinal manifestations and complications of treatment of IBD
Chair: David Wilson
11.00 – 11.30 Dermatology - common and rare presentations: complications of disease & treatment - L. Newell
11.30 – 12.00 Oral manifestations – case presentation - K. Stains
12.00 – 12.30 Growth and pubertal status: is there a role for hormonal treatment - L. Crowe
12.30 – 13.00 Liver complications & management – case presentation - P. van Rheenen
13.00 – 14.00 Lunch
Session 4: Emerging therapies
Chair: Lissy de Ridder
14.00 - 14.30 What about faecal transplant? - E. Wine
14.30 – 15.00 New drugs on the block and their development. Translation from adult to paediatric use and it’s challenges - J. Kammermeier
15.00 – 15.30 Novel dietary treatment; is it feasible? - R. Russell
15.30 – 16.00 Coffee Break
Session 5: Following Guidelines: Interactive case management
Chair: Richard Russell
16.00 – 18.00 (Faculty to present cases x 4)
Early Onset IBD - H. Uhlig
Complex CD - J. van Limbergen
Acute Severe UC - J. Martin de Carpi
Post Operative CD - R. Russell
19.00 Networking & Dinner
